Oct 17,2023 TOP STORY

New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes

DarioHealth announced today new research presented by Sanofi U.S. at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus, demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes. New data presented by Sanofi U.S. at AMCP-Nexus examined matched Dario users and non-users with type 2 diabetes to understand the impact of Dario's digital health solution. The research examined real-world claims data to determine whether users engaged with Dario's solution demonstrated less costly utilization of hospital-related utilization and found 36% reduction in 30-day hospital readmission rate; and 1.6 fewer days in the hospital. The research is part of an ongoing study initiative conducted jointly by Dario and Sanofi U.S., and complements previously published studies presented at ISPOR demonstrating Dario's ability to reduce all-cause healthcare utilization by 9% and inpatient hospitalizations by 23%.

CLINICAL STUDY

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Oct 18,2022

EOFlow Exports EOPatch Production line to Chinese Joint Venture

EOFlow Co., the producer of EOPatch, a small and light wearable insulin pump, has exported an EOPatch production line to its joint venture in China, Sinoflow Co., the company announced on Oct. 17. On Sept. 30, the company shipped equipment to set up an EOPatch production line in Sinoflow, along with materials and semi-assembled parts for trial production of the disposable insulin pump. It also dispatched a small team of manufacturing experts for equipment installation and line construction to China. The EOFlow manufacturing team will set up an EOPatch production line in Sinoflow’s manufacturing facility by the end of November. Sinoflow is currently working on initiating an EOPatch clinical trial in China.

PRODUCT

#insulin pump

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 13,2023

Abbott Focuses on FreeStyle Libre 3 in Germany

Abbott shared that from November 2023 onward the company will be exclusively focusing on its FreeStyle Libre 3 device in Germany, and therefore wants all the FreeStyle Libre and Libre 2 users switch to the company's newest CGM in the market. If prescribed, FreeStyle Libre 3 are covered by almost all health insurances in Germany, while out of pocket price for one sensor is €66 currently.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 20,2022

Dexcom and Abbott’s fight over glucose monitoring patents intensifies in Europe

Dexcom and Abbott are embroiled in a patent dispute over their glucose monitoring devices, with a focus on the UK, Germany, and the US. In Europe, the dispute began when Dexcom filed infringement suits on four of its patents against Abbott in Germany. Abbott counterclaimed by asserting infringement of its patents against Dexcom. The Regional Court Mannheim dismissed one of Abbott's cases against Dexcom due to insufficient evidence of infringement but Abbott has appealed. The legal battle continues, with more cases in progress. In the UK, both companies have challenged each other's patents. The UK High Court is set to try twelve patents across three technical trials, planned for December 2022, April 2023, and July 2023.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 12,2023

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

Women with type 1 diabetes have difficulties achieving the tight glycemic targets required due to their hormonal shifts and changed eating habits during pregnancy. Managing type 1 diabetes currently can result in hypoglycemia, weight gain and high blood pressure in the mother. In the AiDAPT clinical study, women used the CamAPS FX Hybrid Closed Loop technology for more than 95 per cent of the time. Compared to traditional insulin therapy methods, women who used the technology spent more time in the target range for pregnancy glucose levels (3.5 – 7.8 mmol/l) – 68 per cent vs 56 per cent, which is equivalent to an additional two-and-a-half to three hours every day throughout pregnancy, with no increased risk of hypoglycemia. The research team also found that women who used the technology gained 3.5 kg less weight and were less likely to have blood pressure complications during pregnancy.

CLINICAL STUDY

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 12,2023

Glucotrack Announces Preclinical Testing With Implantable Continuous Glucose Monitor

Glucotrack, a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study demonstrating that the CGM sensor design is capable of measuring glucose for at least two years post-implant. The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023 TOP STORY

Sidekick Health announces landmark acquisition, expanding its portfolio to offer Prescription Digital Therapeutics

Icelandic digital health company Sidekick Health is acquiring German prescription digital therapeutics (PDT) company aidhere in a strategic move that places the business directly into the digital prescription space. Aidhere’s weight management app Zanadio is one of the top-performing digital health products within Germany’s regulated nationwide DiGA formulary. As a permanently approved DIGA, the app is reimbursed by all statutory health insurers in Germany and has fulfilled more than 50,000 prescriptions.

COLLABORATION MERGERS & ACQUISITION

#product & service

#dtx

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023 TOP STORY

Virta Health Partners with PBM Navitus Health Solutions to Address Type 2 Diabetes and Obesity Epidemics

Virta Health and pharmacy benefits manager (PBM) Navitus Health Solutions are partnering to bring Virta’s reversal solutions for type 2 diabetes, prediabetes, and obesity to Navitus’ clients. Virta Health highlights in the press release that this announcement underscores the ongoing desire of employers and plan sponsors to address the challenges of metabolic disease within their covered populations, especially amid the rapid growth of GLP-1 medications both for diabetes and weight loss. The partnership addresses this trend. Patients with type 2 diabetes and prediabetes completing one year in Virta’s clinical trial experienced 12% and 13% weight loss, respectively. Virta’s provider-led, nutrition-based solutions will be offered through Navitus to maximize value for clients.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Oct 11,2023 TOP STORY

Noom Extends Its Enterprise Solution with Noom Med

Digital weight loss company Noom announced the expansion of its digital enterprise offering, Noom for Work, to include clinical obesity management solution Noom Med. Noom Med includes psychological tools, community support and content, and access to clinicians with obesity-care training who provide customized weight-loss plans and support for patients in reducing their reliance on GLP-1 medications. "When we have lower acuity users, these are triaged to our psychology-based weight management offering Noom Weight. More moderate needs are triaged to our diabetes prevention program, Noom DPP. Finally, our highest acuity clinical members will be sent to clinical obesity care via Noom Med," Linda Anegawa, chief of medicine at Noom, said.

PRODUCT

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES